Effectiveness of drugs with delayed-release structurally modified action depending on the phenotype of osteoarthritis

Abstract

Aim. To evaluate the effectiveness of a fixed combination of honadroitin and glucosamine sulfate (Teraflex, Bayer) in the treatment of osteoarthritis (OA), depending on the molecular phenotype of the disease.Materials and methods. A 6-month prospective, open, randomized trial included 65 patients with OA of the knee joints who were prescribed therapy with Teraflex (Bayer) daily dose of 1500 mg + 1200 mg. Kinetic assessment of articular status was performed using a visual analogue pain scale and a WOMAC questionnaire, and serum concentrations of CRTAP (cartilage-associated protein), OSGIN-1 (oxidative stress-induced growth inhibitor 1), IL-1β (interleukin-1 beta) were determined in blood serum. Measurements of these parameters were made at the beginning of the study, after 3 and 6 months.Results. It was established that the rate of onset of the therapeutic effect and the effect on the molecular patterns of inflammation and oxidative stress depend on the phenotype of the disease. So, with oxidative and mixed phenotypes of the disease, clinical efficacy is observed in the treatment of teraflex after 3 months from the start of therapy. Indicators of oxidative stress during treatment decreased in the group of patients with the oxidative phenotype of the disease, while the level of interleukin-1 significantly decreased only in groups of patients with inflammatory and mixed OA phenotypes.Conclusions. The results indicate the effectiveness and safety of the drug Teraflex (Bayer) for the treatment of patients with OA. The results of the study indicate the targeted effect of a fixed combination of chondroitin + glucosamine on the molecular mechanisms of the disease.